IMVT
Price
$15.05
Change
+$0.36 (+2.45%)
Updated
Sep 2, 04:40 PM (EDT)
Capitalization
2.56B
59 days until earnings call
XENE
Price
$39.30
Change
+$0.59 (+1.52%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
2.98B
64 days until earnings call
Interact to see
Advertisement

IMVT vs XENE

Header iconIMVT vs XENE Comparison
Open Charts IMVT vs XENEBanner chart's image
Immunovant
Price$15.05
Change+$0.36 (+2.45%)
Volume$860
Capitalization2.56B
Xenon Pharmaceuticals
Price$39.30
Change+$0.59 (+1.52%)
Volume$9.59K
Capitalization2.98B
IMVT vs XENE Comparison Chart in %
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. XENE commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (IMVT: $14.69 vs. XENE: $38.71)
Brand notoriety: IMVT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 65% vs. XENE: 59%
Market capitalization -- IMVT: $2.56B vs. XENE: $2.98B
IMVT [@Biotechnology] is valued at $2.56B. XENE’s [@Biotechnology] market capitalization is $2.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • IMVT’s TA Score: 4 bullish, 5 bearish.
  • XENE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than IMVT.

Price Growth

IMVT (@Biotechnology) experienced а -3.61% price change this week, while XENE (@Biotechnology) price change was -0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +22.16%, and the average quarterly price growth was +32.80%.

Reported Earning Dates

IMVT is expected to report earnings on Oct 31, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.99B) has a higher market cap than IMVT($2.56B). XENE YTD gains are higher at: -1.250 vs. IMVT (-40.694). XENE has higher annual earnings (EBITDA): -315.5M vs. IMVT (-470.69M). IMVT has more cash in the bank: 599M vs. XENE (488M). IMVT has less debt than XENE: IMVT (98K) vs XENE (8.72M). XENE has higher revenues than IMVT: XENE (7.5M) vs IMVT (0).
IMVTXENEIMVT / XENE
Capitalization2.56B2.99B86%
EBITDA-470.69M-315.5M149%
Gain YTD-40.694-1.2503,256%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash599M488M123%
Total Debt98K8.72M1%
FUNDAMENTALS RATINGS
IMVT vs XENE: Fundamental Ratings
IMVT
XENE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
8642
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (39) in the null industry is somewhat better than the same rating for XENE (75) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew somewhat faster than IMVT’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that XENE’s stock grew similarly to IMVT’s over the last 12 months.

XENE's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for IMVT (86) in the null industry. This means that XENE’s stock grew somewhat faster than IMVT’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTXENE
RSI
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 5 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
74%
Momentum
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
77%
MACD
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
85%
Bullish Trend 5 days ago
74%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 15 days ago
74%
BollingerBands
ODDS (%)
N/A
Bearish Trend 5 days ago
78%
Aroon
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSMIX31.790.01
+0.03%
NYLI WMC Value Investor Class
WOOSX18.80-0.06
-0.32%
JPMorgan SMID Cap Equity R6
LGMAX26.11-0.11
-0.42%
Loomis Sayles Global Allocation A
MGICX36.85-0.24
-0.65%
MFS International Intrinsic Value C
ATGYX47.44-0.35
-0.73%
Cantor Fitzgerald Equity Opp Inst

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-0.88%
ROIV - IMVT
60%
Loosely correlated
-0.08%
CGON - IMVT
54%
Loosely correlated
+0.39%
IDYA - IMVT
54%
Loosely correlated
-1.52%
OCUL - IMVT
54%
Loosely correlated
-2.48%
XENE - IMVT
51%
Loosely correlated
+0.28%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.28%
IDYA - XENE
58%
Loosely correlated
-1.52%
CRNX - XENE
55%
Loosely correlated
+1.11%
NRIX - XENE
51%
Loosely correlated
-0.74%
ATXS - XENE
51%
Loosely correlated
-5.36%
ADVM - XENE
51%
Loosely correlated
+1.65%
More